INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
Corporate insider
CR

Chevallard Daniel R.

Chief Financial OfficerCIK 0001706176

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells3 / 0
Max Insider Score50
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
50
CR
Chevallard Daniel R.Chief Financial Officer
LENZLENZ Therapeutics, Inc.
Open-market purchase
BUY$64K
7,500 sh
Mar 27, 2026Mar 30, 2026
traded Mar 27, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    LENZ Therapeutics, Inc.Chief Financial Officer · Nov 7, 2025
34
CR
Chevallard Daniel R.Chief Financial Officer
LENZLENZ Therapeutics, Inc.
Open-market purchase
BUY
$454
20 sh
Nov 7, 2025
Nov 7, 2025
traded Nov 7, 2025
+0d
SEC FORM 4

Evidence

46
CR
Chevallard Daniel R.Chief Financial Officer
LENZLENZ Therapeutics, Inc.
Open-market purchase
BUY$50K
2,178 sh
Nov 7, 2025Nov 7, 2025
traded Nov 7, 2025
+0dSEC FORM 4

Evidence